Efficacy and safety of baricitinib or ravulizumab in adult patients with severe COVID-19 (TACTIC-R): a randomised, parallel-arm, open-label, phase 4 trial
Hall et al., The Lancet Respiratory Medicine, doi:10.1016/S2213-2600(23)00376-4
https://c19early.org/hall3.html